{"id":48432,"date":"2024-01-22T23:00:00","date_gmt":"2024-01-22T22:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/latest-phase-iii-trial-data-investigating-cabometyx-in-combination-with-immunotherapy-to-be-presented-at-asco-gu-2024\/"},"modified":"2024-07-23T12:50:31","modified_gmt":"2024-07-23T10:50:31","slug":"latest-phase-iii-trial-data-investigating-cabometyx-in-combination-with-immunotherapy-to-be-presented-at-asco-gu-2024","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/latest-phase-iii-trial-data-investigating-cabometyx-in-combination-with-immunotherapy-to-be-presented-at-asco-gu-2024\/","title":{"rendered":"Latest Phase III trial data investigating Cabometyx\u00ae in combination with immunotherapy to be presented at ASCO GU 2024"},"content":{"rendered":"